-
Published14/04/2025
-
Today12/05/2025
-
Deadline31/03/2027
-
Opening of tenders31/03/2027
Utilities
- indicates text translated automatically in your browsing language
Medicinal product containing the active substance mepolizumab (ATC: R03DX09) Text automatically translated in your browsing language Automatically translated
The subject of this publication is the conclusion of non-exclusive discount agreements pursuant to § 130a(8) SGB V on finished medicinal products with the active substance aripiprazole (ATC: N05AX12 - for parenteral application) as part of a so-called "open-house model". Subject to uniform contractual conditions and a uniform access procedure, all suitable and interested pharmaceutical companies or communities of pharmaceutical companies are offered the conclusion or accession to a discount contract pursuant to § 130a(8) SGB V for the above-mentioned active substances or medicinal products. Interested pharmaceutical companies can request the participation documents and the respective contract at the mentioned contact address. Prerequisite for the conclusion of a contract is that the interested pharmaceutical company completes and signs the requested participation documents. Text automatically translated in your browsing language Automatically translated
sen-info
This content published on this page is meant purely as an additional service and has no legal effect. The Union's institutions do not assume any liability for its contents. The official versions of the relevant tendering notices are those published in the Supplement of Official Journal of the European Union and available in TED. Those official texts are directly accessible through the links embedded in this page. For more information please see Public Procurement Explainability and Liability notice.